IQVIA Reports Third-Quarter 2026 Results
IQVIA posted record Q3 2026 results with revenue of $4,428 million, up 8.0% YoY, and adjusted diluted EPS of $3.34, up 11.3% -- all headline metrics exceeded the high end of management's expectations. Net new bookings rose 15% to $3.2 billion (1.2x book-to-bill), the strongest clinical quarterly bookings since 2022, and R&DS backlog stands at $32.6 billion with ~$9.4 billion expected to convert to revenue over the next twelve months. The company raised full-year 2026 guidance for revenue ($17.35-$17.50B), adjusted EBITDA ($4.025-$4.055B) and adjusted EPS ($12.90-$13.00), with 250bps of revenue contribution from acquisitions.
Key figures
- Eps
- 2.1
- Revenue
- 4428
- Guidance
- FY2026 revenue $17,350M-$17,500M; Adjusted EBITDA $4,025M-$4,055M; Adjusted Diluted EPS $12.90-$13.00 (raised)
- Revenue Yoy
- 8.0%
- Rd backlog
- $32.6 billion
- Adjusted eps
- 3.34
- Book to bill
- 1.2x
- L TM bookings
- $11.7 billion, up 14%
- Free cash flow
- 667
- Adjusted ebitda
- 1032
- Gaap net income
- 350
- Adjusted eps yoy
- 11.3%
- Net new bookings
- $3.2 billion
- Backlog adjustment
- $2.1 billion (inactive trials review)
- Net leverage ratio
- 3.45x
- Operating cash flow
- 825
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.